• Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

Can an Antibody Against IL13 Be Used to Treat Eosinophilic Esophagitis?

A monoclonal antibody against IL13 reduced histologic and endoscopic features of eosinophilic esophagitis (EoE) in a placebo-controlled phase 2 trial, researchers report in the February issue of Gastroenterology. The antibody, called RPC4046, was well tolerated. EoE is a chronic, immune-mediated disease of the esophagus characterized by eosinophil-mediated mucosal inflammation and

Read more
  • What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

What are the Long-term Effects of DAA Therapy on HCV-associated Cryoglobulinemia Vasculitis?

More than 95% of patients with hepatitis C virus–associated cryoglobulinemia vasculitis (HCV-CryoVas) have a full or partial response of symptoms to treatment with direct-acting antiviral (DAA) agents, researchers report in a long-term follow-up study in the February issue of Clinical Gastroenterology and Hepatology. Fewer than 5% of patients stopped therapy

Read more
  • What is the Best Treatment Option for Fistulizing Crohn’s Disease?

What is the Best Treatment Option for Fistulizing Crohn’s Disease?

Tumor necrosis factor (TNF) antagonists are effective for induction and maintenance of perianal fistula response and remission in patients with Crohn’s disease (CD), a systematic review and meta-analysis shows in the December issue of Clinical Gastoenterology and Hepatology. However, there are few data on the effects on internal fistulae, and further studies

Read more
  • Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

Does Colony Stimulating Factor Increase Survival of Patients with Alcoholic Hepatitis?

In a pilot study from the October issue of Clinical Gastroenterology and Hepatology, colony stimulating factor 3 (CSF3, also called GCSF) improved liver function and increased survival times in patients with severe alcohol-associated hepatitis (AH), compared with standard therapy. Addition of N-acetyl cysteine (NAC) to GCSF did not improve patient outcomes. Patients

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

What are the Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis?

Vitamin K antagonists (VKAs) increase risk of minor bleeding in patients with cirrhosis given anticoagulants for portal vein thrombosis (PVT), compared to patients without cirrhosis given VKAs, researchers report in the July issue of Clinical Gastroenterology and Hepatology. However, this risk is offset by the ability of VKA to increase portal

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more
  • Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Does Pioglitazone Have the Same Effects on NASH in Patients With vs Without Diabetes?

Patients with prediabetes and nonalcoholic steatohepatitis (NASH) benefit nearly as much from pioglitazone therapy as those with type-2 diabetes, researchers report in the April issue of Clinical Gastroenterology and Hepatology. The diabetes drug reduced fibrosis in non-diabetic patients with NASH, the clinical study found, although to a lesser extent than in patients

Read more
  • Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Endoscopic therapy of T1a esophageal adenocarcinoma (EAC) yields more quality-adjusted life years (QALYs) and is more cost effective than esophagectomy, shows a Markov model analysis published in the March issue of Clinical Gastroenterology and Hepatology. However, therapy for T1b EAC should be selected based on patients’ age and comorbidities. Although EAC has

Read more
  • Developing a New Combination Treatment for HBV Infection

Developing a New Combination Treatment for HBV Infection

NVR3–778, a capsid assembly modulator, reduces serum levels of hepatitis B virus (HBV) DNA and HBV RNA in mice with humanized livers and stable HBV infection, researchers report in the February issue of Gastroenterology. The combination of NVR3–778 and interferon prevented viral replication and HBV RNA particle production to a greater extent than

Read more